root cause – Page 125

Visual inspection rejects during PAI readiness – FDA/MHRA inspection outcome

Analyzing Visual Inspection Rejects During PAI Readiness for Regulatory Success In the highly regulated world of pharmaceutical manufacturing, visual inspection plays a critical role in ensuring product quality and compliance…

Particulate matter detected during stability testing – patient safety risk analysis

Analyzing Particulate Matter Detected During Stability Testing: A Comprehensive Investigation Detecting particulate matter during stability testing is a significant concern in pharmaceutical manufacturing, particularly for injectable products. This issue not…

Endotoxin OOS after line intervention – CAPA effectiveness failure

Investigation of Endotoxin OOS Following Line Intervention: Ensuring CAPA Effectiveness In the pharmaceutical manufacturing landscape, addressing Out of Specification (OOS) results is paramount, especially when related to endotoxin testing following…

Particulate matter detected after line intervention – patient safety risk analysis

Analyzing Particulate Matter Detection Post-Line Intervention: An Investigation Approach In the pharmaceutical manufacturing sector, the detection of particulate matter in injectable products can signal alarming risks to patient safety and…

Fill volume variability during stability testing – patient safety risk analysis

Managing Fill Volume Variability During Stability Testing: A Comprehensive Investigation Guide Variability in fill volume during stability testing poses significant risks to product integrity and patient safety. Pharmaceutical professionals must…

Visual inspection rejects post-sterile filtration – patient safety risk analysis

Analyzing Visual Inspection Rejections Post-Sterile Filtration: A Structured Approach Visual inspection is a crucial process in pharmaceutical manufacturing, especially for injectable products. When product batches are rejected due to visual…

Endotoxin OOS during PAI readiness – FDA/MHRA inspection outcome

Investigation of Endotoxin OOS in PAI Readiness for Successful FDA/MHRA Outcomes In the fast-paced world of pharmaceutical manufacturing, ensuring the sterility and safety of injectable products is paramount. A common…

Visual inspection rejects during stability testing – FDA/MHRA inspection outcome

Understanding Visual Inspection Rejects During Stability Testing: An In-Depth Investigation Visual inspection rejects during stability testing can signal significant issues within a pharmaceutical manufacturing process. These rejects not only impact…

pH drift detected during stability testing – FDA/MHRA inspection outcome

Investigation of pH Drift Detected During Stability Testing: Implications for Compliance and Quality In the pharmaceutical manufacturing environment, maintaining established product specifications is paramount to ensuring product quality and compliance…

Dissolution failure during inspection prep – manufacturing vs material root cause

Dissolution Failures During Inspection Preparation: An In-Depth Investigation Dissolution failure during inspection preparation is a critical issue that can significantly impact the manufacturing process and product compliance. This article aims…

Capsule leakage complaint during bulk storage – CAPA inadequacy explained

Addressing Capsule Leakage Complaints during Bulk Storage: A Comprehensive Investigation Approach Capsule manufacturing defects, specifically relating to leakage during bulk storage, can have serious implications for product quality, regulatory compliance,…

Dissolution failure after supplier change – CAPA inadequacy explained

Dissolution Failure Following Supplier Change: Understanding CAPA Inadequacy Manufacturers often face quality issues, including dissolution failures, especially after changing suppliers. Such scenarios can trigger significant deviations and out-of-specification (OOS) results…